These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18327222)

  • 41. Great company, bad stock.
    Jacobs T
    Nat Biotechnol; 2005 Feb; 23(2):173. PubMed ID: 15696142
    [No Abstract]   [Full Text] [Related]  

  • 42. How the street sees biotech.
    Lashinsky A
    Fortune; 2003 Jun; 147(11):86. PubMed ID: 12800576
    [No Abstract]   [Full Text] [Related]  

  • 43. Pharmaceutical industry must take its medicine.
    Macilwain C
    Nature; 2011 Feb; 470(7333):141. PubMed ID: 21307893
    [No Abstract]   [Full Text] [Related]  

  • 44. Biotech's wonder ride.
    Rynecki D
    Fortune; 2000 Mar; 141(5):435-6. PubMed ID: 10788046
    [No Abstract]   [Full Text] [Related]  

  • 45. Finding new life in health stocks.
    Armour LA
    Fortune; 1997 Sep; 136(6):289-90, 292, 294. PubMed ID: 10173398
    [No Abstract]   [Full Text] [Related]  

  • 46. Bugs or drugs, tortoises or hares?
    Jacobs T
    Nat Biotechnol; 2005 Mar; 23(3):293. PubMed ID: 15765079
    [No Abstract]   [Full Text] [Related]  

  • 47. The stampede to convertibles.
    Jacobs T
    Nat Biotechnol; 2003 Aug; 21(8):855. PubMed ID: 12894195
    [No Abstract]   [Full Text] [Related]  

  • 48. Public biotech 98: the numbers.
    Lähteenmäki R; Michael A; Marshall A
    Nat Biotechnol; 1999 May; 17(5):429-32. PubMed ID: 10331795
    [No Abstract]   [Full Text] [Related]  

  • 49. When your stock takes a nosedive.
    Jacobs T
    Nat Biotechnol; 2006 Feb; 24(2):144. PubMed ID: 16465152
    [No Abstract]   [Full Text] [Related]  

  • 50. A rollercoaster ride.
    Jacobs T
    Nat Biotechnol; 2006 Mar; 24(3):284. PubMed ID: 16525390
    [No Abstract]   [Full Text] [Related]  

  • 51. 25 top health care stocks. Will they lead the next market boom?
    Kane L
    Med Econ; 2001 Apr; 78(7):126-8, 133-6, 140-2. PubMed ID: 11368040
    [No Abstract]   [Full Text] [Related]  

  • 52. Antibiotics--an investment worth making?
    Christoffersen RE
    Nat Biotechnol; 2006 Dec; 24(12):1512-4. PubMed ID: 17160052
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The 802 million dollars fallacy.
    Hodgson J
    Nat Biotechnol; 2004 Sep; 22(9):1076. PubMed ID: 15340464
    [No Abstract]   [Full Text] [Related]  

  • 54. Barnyard biotech--lame duck or golden goose?
    Powell K
    Nat Biotechnol; 2003 Sep; 21(9):965-7. PubMed ID: 12949546
    [No Abstract]   [Full Text] [Related]  

  • 55. Russian fund steps up investments in innovative biotechs.
    Katsnelson A
    Nat Biotechnol; 2012 Jan; 30(1):9-11. PubMed ID: 22231078
    [No Abstract]   [Full Text] [Related]  

  • 56. Biotech plummets in 3Q11.
    Yang W
    Nat Biotechnol; 2011 Nov; 29(11):962. PubMed ID: 22068525
    [No Abstract]   [Full Text] [Related]  

  • 57. Any diamonds in the diagnostic coal?
    Jacobs T
    Nat Biotechnol; 2006 Aug; 24(8):930. PubMed ID: 16900133
    [No Abstract]   [Full Text] [Related]  

  • 58. Biotech jostles with pharma for slice of HIV market.
    Katsnelson A
    Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375
    [No Abstract]   [Full Text] [Related]  

  • 59. Biotech stocks struggle as financial markets tumble.
    Mitchell P
    Nat Biotechnol; 2002 Aug; 20(8):755-6. PubMed ID: 12147984
    [No Abstract]   [Full Text] [Related]  

  • 60. Public biotech 2018-the numbers.
    Morrison C; Lähteenmäki R
    Nat Biotechnol; 2019 Jul; 37(7):714-721. PubMed ID: 31227821
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.